Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Florian Huemer (First author), Simon Peter Gampenrieder (Co-author), Alexander Schlattau (Co-author), Richard Greil (Last author)

Research output: Contribution to journalCase reportpeer-review

Original languageEnglish
Pages (from-to)e17-e20
JournalCLINICAL BREAST CANCER
Volume14
Issue number1
DOIs
Publication statusPublished - 2014

Cite this